Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg(6),D-Trp(7,9),N(me)Phe(8)]-substance P (6–11)-induced growth inhibition

[Arg(6),D-Trp(7,9),N(me)Phe(8)]-substance P (6–11) (SP-G) is a novel anticancer agent that has recently completed phase I clinical trials. SP-G inhibits mitogenic neuropeptide signal transduction and small cell lung cancer (SCLC) cell growth in vitro and in vivo. Using the SCLC cell line series GLC1...

Descripción completa

Detalles Bibliográficos
Autores principales: Waters, C M, MacKinnon, A C, Cummings, J, Tufail-Hanif, U, Jodrell, D, Haslett, C, Sethi, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377129/
https://www.ncbi.nlm.nih.gov/pubmed/12771999
http://dx.doi.org/10.1038/sj.bjc.6600957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377129/
https://www.ncbi.nlm.nih.gov/pubmed/12771999
http://dx.doi.org/10.1038/sj.bjc.6600957

Ejemplares similares